نتائج البحث - "Sergey Alekseevich Selkov"

العلاقة: https://www.mimmun.ru/mimmun/article/view/2923/1920Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13088Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13089Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13090Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13091Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13092Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13093Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13094Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13134Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13135Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13155Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13156Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13546Test; Abramiuk M., Bebnowska D., Hrynkiewicz R., Polak P.N.G., Kotarski J., Rolinski J.,Grywalska E. CLTA-4 Expression is Associated with the Maintenance of Chronic Inflammation in Endometriosis and Infertility. Cells, 2021, Vol.10, no 3. [10.3390/cells10030487] https://www.ncbi.nlm.nih.gov/pubmed/33668701Test; Abramiuk M., Frankowska K., Kulak K., Tarkowski R., Mertowska P., Mertowski S.,Grywalska E. Possible Correlation between Urocortin 1 (Ucn1) and Immune Parameters in Patients with Endometriosis. Int J Mol Sci, 2023, Vol.24, no 9. [10.3390/ijms24097787] https://www.ncbi.nlm.nih.gov/pubmed/37175494Test; Agic A., Djalali S., Wolfler M.M., Halis G., Diedrich K.,Hornung D. Combination of CCR1 mRNA, MCP1, and CA125 measurements in peripheral blood as a diagnostic test for endometriosis. Reprod Sci, 2008, Vol.15, no 9, pp. 906-11. [10.1177/1933719108318598] https://www.ncbi.nlm.nih.gov/pubmed/19050323Test; Akhtar K., Sravanthi M.V., D'Angelo J.,Sivapiragasam A. Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios. J Investig Med High Impact Case Rep, 2022, Vol.10, no, pp. 23247096221121408. [10.1177/23247096221121408] https://www.ncbi.nlm.nih.gov/pubmed/36017984Test; Akinboro O., Larkins E., Pai-Scherf L.H., Mathieu L.N., Ren Y., Cheng J., Fiero M.H., Fu W., Bi Y., Kalavar S., Jafri S., Mishra-Kalyani P.S., Fourie Zirkelbach J., Li H., Zhao H., He K., Helms W.S., Chuk M.K., Wang M., Bulatao I., Herz J., Osborn B.L., Xu Y., Liu J., Gong Y., Sickafuse S., Cohen R., Donoghue M., Pazdur R., Beaver J.A.,Singh H. FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC. Clin Cancer Res, 2022, Vol.28, no 11, pp. 2221-2228. [10.1158/1078-0432.CCR-21-3844] https://www.ncbi.nlm.nih.gov/pubmed/35101885Test; Alsharedi M., Srivastava R.,Elmsherghi N. Durvalumab for the treatment of urothelial carcinoma. Drugs Today (Barc), 2017, Vol.53, no 12, pp. 647-652. [10.1358/dot.2017.53.12.2733054] https://www.ncbi.nlm.nih.gov/pubmed/29517083Test; Anglesio M.S., Papadopoulos N., Ayhan A., Nazeran T.M., Noe M., Horlings H.M., Lum A., Jones S., Senz J., Seckin T., Ho J., Wu R.C., Lac V., Ogawa H., Tessier-Cloutier B., Alhassan R., Wang A., Wang Y., Cohen J.D., Wong F., Hasanovic A., Orr N., Zhang M., Popoli M., McMahon W., Wood L.D., Mattox A., Allaire C., Segars J., Williams C., Tomasetti C., Boyd N., Kinzler K.W., Gilks C.B., Diaz L., Wang T.L., Vogelstein B., Yong P.J., Huntsman D.G.,Shih I.M. Cancer-Associated Mutations in Endometriosis without Cancer. N Engl J Med, 2017, Vol.376, no 19, pp. 1835-1848. [10.1056/NEJMoa1614814] https://www.ncbi.nlm.nih.gov/pubmed/28489996Test; Arabpour M., Ghods A., Shariat M., Talei A.R., Mehdipour F.,Ghaderi A. Correlation of 4-1BBL+ B Cells in Tumor Draining Lymph Nodes with Pathological Characteristics of Breast Cancer. Iran J Immunol, 2019, Vol.16, no 2, pp. 108-116. [10.22034/IJI.2019.80254] https://www.ncbi.nlm.nih.gov/pubmed/31182685Test; Atkinson V., Khattak A., Haydon A., Eastgate M., Roy A., Prithviraj P., Mueller C., Brignone C.,Triebel F. Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. J Immunother Cancer, 2020, Vol.8, no 2. [10.1136/jitc-2020-001681] https://www.ncbi.nlm.nih.gov/pubmed/33219094Test; Azimnasab-Sorkhabi P., Soltani-Asl M.,Kfoury Junior J.R. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) as an undetermined tool in tumor cells. Hum Cell, 2023, Vol.36, no 4, pp. 1225-1232. [10.1007/s13577-023-00893-8] https://www.ncbi.nlm.nih.gov/pubmed/36907978Test; Baptista M.Z., Sarian L.O., Derchain S.F., Pinto G.A.,Vassallo J. Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum Pathol, 2016, Vol.47, no 1, pp. 78-84. [10.1016/j.humpath.2015.09.006] https://www.ncbi.nlm.nih.gov/pubmed/26541326Test; Bardhan K., Anagnostou T.,Boussiotis V.A. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol, 2016, Vol.7, no, pp. 550. [10.3389/fimmu.2016.00550] https://www.ncbi.nlm.nih.gov/pubmed/28018338Test; Barra F., Ferro Desideri L., Leone Roberti Maggiore U., Gaetano Vellone V., Maramai M., Scala C.,Ferrero S. Endometriosis Classification and The Role of Tumor Necrosis Factor-Alpha Polymorphisms as A Therapeutic Target. Int J Fertil Steril, 2020, Vol.14, no 1, pp. 76-77. [10.22074/ijfs.2020.5876] https://www.ncbi.nlm.nih.gov/pubmed/32112641Test; Bartkowiak T.,Curran M.A. 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol, 2015, Vol.5, no, pp. 117. [10.3389/fonc.2015.00117] https://www.ncbi.nlm.nih.gov/pubmed/26106583Test; Bettini M., Szymczak-Workman A.L., Forbes K., Castellaw A.H., Selby M., Pan X., Drake C.G., Korman A.J.,Vignali D.A. Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3. J Immunol, 2011, Vol.187, no 7, pp. 3493-8. [10.4049/jimmunol.1100714] https://www.ncbi.nlm.nih.gov/pubmed/21873518Test; Borrelli G.M., Abrao M.S.,Mechsner S. Can chemokines be used as biomarkers for endometriosis? A systematic review. Hum Reprod, 2014, Vol.29, no 2, pp. 253-66. [10.1093/humrep/det401] https://www.ncbi.nlm.nih.gov/pubmed/24287816Test; Brinton L.A., Gridley G., Persson I., Baron J.,Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol, 1997, Vol.176, no 3, pp. 572-9. [10.1016/s0002-9378(97)70550-7] https://www.ncbi.nlm.nih.gov/pubmed/9077609Test; Brinton L.A., Sakoda L.C., Sherman M.E., Frederiksen K., Kjaer S.K., Graubard B.I., Olsen J.H.,Mellemkjaer L. Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors. Cancer Epidemiol Biomarkers Prev, 2005, Vol.14, no 12, pp. 2929-35. [10.1158/1055-9965.EPI-05-0394] https://www.ncbi.nlm.nih.gov/pubmed/16365012Test; Brubel R., Bokor A., Pohl A., Schilli G.K., Szereday L., Bacher-Szamuel R., Rigo J., Jr.,Polgar B. Serum galectin-9 as a noninvasive biomarker for the detection of endometriosis and pelvic pain or infertility-related gynecologic disorders. Fertil Steril, 2017, Vol.108, no 6, pp. 1016-1025 e2. [10.1016/j.fertnstert.2017.09.008] https://www.ncbi.nlm.nih.gov/pubmed/29202955Test; Burghaus S., Drazic P., Wolfler M., Mechsner S., Zeppernick M., Meinhold-Heerlein I., Mueller M.D., Rothmund R., Vigano P., Becker C.M., Zondervan K.T., Beckmann M.W., Fasching P.A., Berner-Gatz S., Grunewald F.S., Hund M., Kastner P., Klammer M., Laubender R.P., Wegmeyer H., Wienhues-Thelen U.H.,Renner S.P. Multicenter evaluation of blood-based biomarkers for the detection of endometriosis and adenomyosis: A prospective non-interventional study. Int J Gynaecol Obstet, 2023 no. [10.1002/ijgo.15062] https://www.ncbi.nlm.nih.gov/pubmed/37635683Test; Cakir Y., Talu C.K., Trabulus D.C.,Mermut O. The immunohistochemical Galectin-3 expression in tumor and cancer-associated fibroblasts in invasive ductal carcinomas of breast and their relationship with clinicopathological parameters. Indian J Pathol Microbiol, 2023, Vol.66, no 3, pp. 456-464. [10.4103/ijpm.ijpm_284_21] https://www.ncbi.nlm.nih.gov/pubmed/37530324Test; Canales Rojas R. Update on immunotherapy for renal cancer. Medwave, 2021, Vol.21, no 5, pp. e8202. [10.5867/medwave.2021.05.8202] https://www.ncbi.nlm.nih.gov/pubmed/34214067Test; Cao Y., Zhou X., Huang X., Li Q., Gao L., Jiang L., Huang M.,Zhou J. Tim-3 expression in cervical cancer promotes tumor metastasis. PLoS One, 2013, Vol.8, no 1, pp. e53834. [10.1371/journal.pone.0053834] https://www.ncbi.nlm.nih.gov/pubmed/23335978Test; Caserta D., Di Benedetto L., Bordi G., D'Ambrosio A.,Moscarini M. Levels of Galectin-3 and Stimulation Expressed Gene 2 in the peritoneal fluid of women with endometriosis: a pilot study. Gynecol Endocrinol, 2014, Vol.30, no 12, pp. 877-80. [10.3109/09513590.2014.943728] https://www.ncbi.nlm.nih.gov/pubmed/25069762Test; Chambers C.A., Kuhns M.S., Egen J.G.,Allison J.P. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol, 2001, Vol.19, no, pp. 565-94. [10.1146/annurev.immunol.19.1.565] https://www.ncbi.nlm.nih.gov/pubmed/11244047Test; Chattopadhyay S.,Chakraborty N.G. GITR expression on T-cell receptor-stimulated human CD8 T cell in a JNK-dependent pathway. Indian J Hum Genet, 2009, Vol.15, no 3, pp. 121-4. [10.4103/0971-6866.60188] https://www.ncbi.nlm.nih.gov/pubmed/21088717Test; Chen S., Liu Y., Zhong Z., Wei C., Liu Y.,Zhu X. Peritoneal immune microenvironment of endometriosis: Role and therapeutic perspectives. Front Immunol, 2023, Vol.14, no, pp. 1134663. [10.3389/fimmu.2023.1134663] https://www.ncbi.nlm.nih.gov/pubmed/36865552Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971222/pdf/fimmu-14-1134663.pdfTest; Chen T., Wei J.L., Leng T., Gao F.,Hou S.Y. The diagnostic value of the combination of hemoglobin, CA199, CA125, and HE4 in endometriosis. J Clin Lab Anal, 2021, Vol.35, no 9, pp. e23947. [10.1002/jcla.23947] https://www.ncbi.nlm.nih.gov/pubmed/34405450Test; Chen W.C., Cheng C.M., Liao W.T.,Chang T.C. Urinary Biomarkers for Detection of Clinical Endometriosis or Adenomyosis. Biomedicines, 2022, Vol.10, no 4. [10.3390/biomedicines10040833] https://www.ncbi.nlm.nih.gov/pubmed/35453583Test; https://mdpi-res.com/d_attachment/biomedicines/biomedicines-10-00833/article_deploy/biomedicines-10-00833.pdf?version=1648819036Test; Chen X., Du Y., Hu Q.,Huang Z. Tumor-derived CD4+CD25+regulatory T cells inhibit dendritic cells function by CTLA-4. Pathol Res Pract, 2017, Vol.213, no 3, pp. 245-249. [10.1016/j.prp.2016.12.008] https://www.ncbi.nlm.nih.gov/pubmed/28214198Test; Chen Z., Huang J., Kwak-Kim J.,Wang W. Immune checkpoint inhibitors and reproductive failures. J Reprod Immunol, 2023, Vol.156, no, pp. 103799. [10.1016/j.jri.2023.103799] https://www.ncbi.nlm.nih.gov/pubmed/36724630Test; Cheng L.S., Cheng Y.F., Liu W.T., Shen A., Zhang D., Xu T., Yin W., Cheng M., Ma X., Wang F., Zhao Q., Zeng X., Zhang Y.,Shen G. A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity. J Transl Med, 2022, Vol.20, no 1, pp. 415. [10.1186/s12967-022-03619-w] https://www.ncbi.nlm.nih.gov/pubmed/36076251Test; Chester C., Ambulkar S.,Kohrt H.E. 4-1BB agonism: adding the accelerator to cancer immunotherapy. Cancer Immunol Immunother, 2016, Vol.65, no 10, pp. 1243-8. [10.1007/s00262-016-1829-2] https://www.ncbi.nlm.nih.gov/pubmed/27034234Test; Chester C., Sanmamed M.F., Wang J.,Melero I. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood, 2018, Vol.131, no 1, pp. 49-57. [10.1182/blood-2017-06-741041] https://www.ncbi.nlm.nih.gov/pubmed/29118009Test; Choi Y.S., Kim S., Oh Y.S., Cho S.,Hoon Kim S. Elevated serum interleukin-32 levels in patients with endometriosis: A cross-sectional study. Am J Reprod Immunol, 2019, Vol.82, no 2, pp. e13149. [10.1111/aji.13149] https://www.ncbi.nlm.nih.gov/pubmed/31099938Test; Claus C., Ferrara-Koller C.,Klein C. The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy. MAbs, 2023, Vol.15, no 1, pp. 2167189. [10.1080/19420862.2023.2167189] https://www.ncbi.nlm.nih.gov/pubmed/36727218Test; Collins J.M.,Gulley J.L. Product review: avelumab, an anti-PD-L1 antibody. Hum Vaccin Immunother, 2019, Vol.15, no 4, pp. 891-908. [10.1080/21645515.2018.1551671] https://www.ncbi.nlm.nih.gov/pubmed/30481100Test; Contardi E., Palmisano G.L., Tazzari P.L., Martelli A.M., Fala F., Fabbi M., Kato T., Lucarelli E., Donati D., Polito L., Bolognesi A., Ricci F., Salvi S., Gargaglione V., Mantero S., Alberghini M., Ferrara G.B.,Pistillo M.P. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer, 2005, Vol.117, no 4, pp. 538-50. [10.1002/ijc.21155] https://www.ncbi.nlm.nih.gov/pubmed/15912538Test; Daud A.I., Wolchok J.D., Robert C., Hwu W.J., Weber J.S., Ribas A., Hodi F.S., Joshua A.M., Kefford R., Hersey P., Joseph R., Gangadhar T.C., Dronca R., Patnaik A., Zarour H., Roach C., Toland G., Lunceford J.K., Li X.N., Emancipator K., Dolled-Filhart M., Kang S.P., Ebbinghaus S.,Hamid O. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol, 2016, Vol.34, no 34, pp. 4102-4109. [10.1200/JCO.2016.67.2477] https://www.ncbi.nlm.nih.gov/pubmed/27863197Test; De Mello R.A.B., Voscaboinik R., Luciano J.V.P., Cremonese R.V., Amaral G.A., Castelo-Branco P.,Antoniou G. Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives. Cancers (Basel), 2021, Vol.14, no 1. [10.3390/cancers14010122] https://www.ncbi.nlm.nih.gov/pubmed/35008287Test; Duan X., Liu J., Cui J., Ma B., Zhou Q., Yang X., Lu Z., Du Y.,Su C. Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma. Mol Med Rep, 2019, Vol.20, no 4, pp. 3773-3781. [10.3892/mmr.2019.10641] https://www.ncbi.nlm.nih.gov/pubmed/31485637Test; Dumic J., Dabelic S.,Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta, 2006, Vol.1760, no 4, pp. 616-35. [10.1016/j.bbagen.2005.12.020] https://www.ncbi.nlm.nih.gov/pubmed/16478649Test; Eggermont A.M.,Robert C. New drugs in melanoma: it's a whole new world. Eur J Cancer, 2011, Vol.47, no 14, pp. 2150-7. [10.1016/j.ejca.2011.06.052] https://www.ncbi.nlm.nih.gov/pubmed/21802280Test; Eurich K., De La Cruz P., Laguna A., Woodman M., McAdams J., Lips E., Ebott J., DiSilvestro J., Ribeiro J.,James N. Multiplex serum immune profiling reveals circulating LAG-3 is associated with improved patient survival in high grade serous ovarian cancer. Gynecol Oncol, 2023, Vol.174, no, pp. 200-207. [10.1016/j.ygyno.2023.05.015] https://www.ncbi.nlm.nih.gov/pubmed/37224792Test; Finkelmeier F., Waidmann O.,Trojan J. Nivolumab for the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther, 2018, Vol.18, no 12, pp. 1169-1175. [10.1080/14737140.2018.1535315] https://www.ncbi.nlm.nih.gov/pubmed/30304963Test; Geng H., Zhang G.M., Xiao H., Yuan Y., Li D., Zhang H., Qiu H., He Y.F.,Feng Z.H. HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma. Int J Cancer, 2006, Vol.118, no 11, pp. 2657-64. [10.1002/ijc.21795] https://www.ncbi.nlm.nih.gov/pubmed/16425224Test; Gu Q., Li J., Chen Z., Zhang J., Shen H., Miao X., Zhou Y., Xu X.,He S. Expression and Prognostic Significance of PD-L2 in Diffuse Large B-Cell Lymphoma. Front Oncol, 2021, Vol.11, no, pp. 664032. [10.3389/fonc.2021.664032] https://www.ncbi.nlm.nih.gov/pubmed/34178648Test; Guney G., Taskin M.I., Lagana A.S., Tolu E., Aslan F., Hismiogullari A.A.,Kaya C. Neutrophil gelatinase-associated lipocalin serum level: A potential noninvasive biomarker of endometriosis? Medicine (Baltimore), 2023, Vol.102, no 41, pp. e35539. [10.1097/MD.0000000000035539] https://www.ncbi.nlm.nih.gov/pubmed/37832065Test; Guo B., Chen J.H., Zhang J.H., Fang Y., Liu X.J., Zhang J., Zhu H.Q.,Zhan L. Pattern-recognition receptors in endometriosis: A narrative review. Front Immunol, 2023, Vol.14, no, pp. 1161606. [10.3389/fimmu.2023.1161606] https://www.ncbi.nlm.nih.gov/pubmed/37033937Test; Gurney A.L., Marsters S.A., Huang R.M., Pitti R.M., Mark D.T., Baldwin D.T., Gray A.M., Dowd A.D., Brush A.D., Heldens A.D., Schow A.D., Goddard A.D., Wood W.I., Baker K.P., Godowski P.J.,Ashkenazi A. Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol, 1999, Vol.9, no 4, pp. 215-8. [10.1016/s0960-9822(99)80093-1] https://www.ncbi.nlm.nih.gov/pubmed/10074428Test; Hafler D.A.,Kuchroo V. TIMs: central regulators of immune responses. J Exp Med, 2008, Vol.205, no 12, pp. 2699-701. [10.1084/jem.20082429] https://www.ncbi.nlm.nih.gov/pubmed/19015312Test; Hamanishi J., Mandai M., Iwasaki M., Okazaki T., Tanaka Y., Yamaguchi K., Higuchi T., Yagi H., Takakura K., Minato N., Honjo T.,Fujii S. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A, 2007, Vol.104, no 9, pp. 3360-5. [10.1073/pnas.0611533104] https://www.ncbi.nlm.nih.gov/pubmed/17360651Test; He Y., Jia K., Dziadziuszko R., Zhao S., Zhang X., Deng J., Wang H., Hirsch F.R.,Zhou C. Galectin-9 in non-small cell lung cancer. Lung Cancer, 2019, Vol.136, no, pp. 80-85. [10.1016/j.lungcan.2019.08.014] https://www.ncbi.nlm.nih.gov/pubmed/31454748Test; He Y., Rivard C.J., Rozeboom L., Yu H., Ellison K., Kowalewski A., Zhou C.,Hirsch F.R. Lymphocyte-activation gene-3, an important immune checkpoint in cancer. Cancer Sci, 2016, Vol.107, no 9, pp. 1193-7. [10.1111/cas.12986] https://www.ncbi.nlm.nih.gov/pubmed/27297395Test; Hemon P., Jean-Louis F., Ramgolam K., Brignone C., Viguier M., Bachelez H., Triebel F., Charron D., Aoudjit F., Al-Daccak R.,Michel L. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol, 2011, Vol.186, no 9, pp. 5173-83. [10.4049/jimmunol.1002050] https://www.ncbi.nlm.nih.gov/pubmed/21441454Test; Henry L., Vervier J., Boucher A., Brichant G., Gaspard O., Labied S., Munaut C., Ravet S.,Nisolle M. Oocyte Cryopreservation in Patients with Endometriosis: Current Knowledge and Number Needed to Treat. J Clin Med, 2022, Vol.11, no 15. [10.3390/jcm11154559] https://www.ncbi.nlm.nih.gov/pubmed/35956174Test; Hong J.H., Cho H.W., Ouh Y.T., Lee J.K.,Chun Y. Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancer. J Gynecol Oncol, 2023, Vol.34, no 2, pp. e18. [10.3802/jgo.2023.34.e18] https://www.ncbi.nlm.nih.gov/pubmed/36509464Test; Huang R.Y., Francois A., McGray A.R., Miliotto A.,Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology, 2017, Vol.6, no 1, pp. e1249561. [10.1080/2162402X.2016.1249561] https://www.ncbi.nlm.nih.gov/pubmed/28197366Test; Huo J.L., Wang Y.T., Fu W.J., Lu N.,Liu Z.S. The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. Front Immunol, 2022, Vol.13, no, pp. 956090. [10.3389/fimmu.2022.956090] https://www.ncbi.nlm.nih.gov/pubmed/35958563Test; Incognito G.G., Di Guardo F., Gulino F.A., Genovese F., Benvenuto D., Lello C.,Palumbo M. Interleukin-6 as A Useful Predictor of Endometriosis-Associated Infertility: A Systematic Review. Int J Fertil Steril, 2023, Vol.17, no 4, pp. 226-230. [10.22074/ijfs.2023.557683.1329] https://www.ncbi.nlm.nih.gov/pubmed/37577903Test; Jansa V., Pusic Novak M., Ban Frangez H.,Rizner T.L. TGFBI as a candidate biomarker for non-invasive diagnosis of early-stage endometriosis. Hum Reprod, 2023, Vol.38, no 7, pp. 1284-1296. [10.1093/humrep/dead091] https://www.ncbi.nlm.nih.gov/pubmed/37187159Test; Jarollahi S., Chaichian S., Jarollahi A., Hajmohammadi R., Mashayekhi R., Shahmohammadi F., Eslamivaghar M.,Ghasemi Z. The Diagnostic Accuracy of Galectin-9 for Diagnosis of Endometriosis in Comparison with Laparoscopy. J Reprod Infertil, 2022, Vol.23, no 4, pp. 271-278. [10.18502/jri.v23i4.10812] https://www.ncbi.nlm.nih.gov/pubmed/36452187Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674464/pdf/JRI-23-271.pdfTest; Jeung I., Cheon K.,Kim M.R. Decreased Cytotoxicity of Peripheral and Peritoneal Natural Killer Cell in Endometriosis. Biomed Res Int, 2016, Vol.2016, no, pp. 2916070. [10.1155/2016/2916070] https://www.ncbi.nlm.nih.gov/pubmed/27294113Test; Jiang J., Jiang Z.,Xue M. Serum and peritoneal fluid levels of interleukin-6 and interleukin-37 as biomarkers for endometriosis. Gynecol Endocrinol, 2019, Vol.35, no 7, pp. 571-575. [10.1080/09513590.2018.1554034] https://www.ncbi.nlm.nih.gov/pubmed/30632819Test; Jolicoeur C., Boutouil M., Drouin R., Paradis I., Lemay A.,Akoum A. Increased expression of monocyte chemotactic protein-1 in the endometrium of women with endometriosis. Am J Pathol, 1998, Vol.152, no 1, pp. 125-33. https://www.ncbi.nlm.nih.gov/pubmed/9422530Test; Kang C. Retifanlimab: First Approval. Drugs, 2023, Vol.83, no 8, pp. 731-737. [10.1007/s40265-023-01884-7] https://www.ncbi.nlm.nih.gov/pubmed/37184754Test; Kang Y.J., Jeung I.C., Park A., Park Y.J., Jung H., Kim T.D., Lee H.G., Choi I.,Yoon S.R. An increased level of IL-6 suppresses NK cell activity in peritoneal fluid of patients with endometriosis via regulation of SHP-2 expression. Hum Reprod, 2014, Vol.29, no 10, pp. 2176-89. [10.1093/humrep/deu172] http://www.ncbi.nlm.nih.gov/pubmed/25035432Test; Kaya C., Alay I., Guraslan H., Gedikbasi A., Ekin M., Ertas Kaya S., Oral E.,Yasar L. The Role of Serum Caspase 3 Levels in Prediction of Endometriosis Severity. Gynecol Obstet Invest, 2018, Vol.83, no 6, pp. 576-585. [10.1159/000489494] https://www.ncbi.nlm.nih.gov/pubmed/30071521Test; Keir M.E., Butte M.J., Freeman G.J.,Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol, 2008, Vol.26, no, pp. 677-704. [10.1146/annurev.immunol.26.021607.090331] https://www.ncbi.nlm.nih.gov/pubmed/18173375Test; Kimber-Trojnar Z., Pilszyk A., Niebrzydowska M., Pilszyk Z., Ruszala M.,Leszczynska-Gorzelak B. The Potential of Non-Invasive Biomarkers for Early Diagnosis of Asymptomatic Patients with Endometriosis. J Clin Med, 2021, Vol.10, no 13. [10.3390/jcm10132762] https://www.ncbi.nlm.nih.gov/pubmed/34201813Test; Kong F., Jin M., Cao D., Jia Z., Liu Y.,Jiang J. Galectin-3 not Galectin-9 as a candidate prognosis marker for hepatocellular carcinoma. PeerJ, 2020, Vol.8, no, pp. e9949. [10.7717/peerj.9949] https://www.ncbi.nlm.nih.gov/pubmed/32995093Test; Kovalak E.E., Karacan T., Zengi O., Karabay Akgul O., Ozyurek S.E.,Guraslan H. Evaluation of new biomarkers in stage III and IV endometriosis. Gynecol Endocrinol, 2023, Vol.39, no 1, pp. 2217290. [10.1080/09513590.2023.2217290] https://www.ncbi.nlm.nih.gov/pubmed/37236244Test; Krummel M.F.,Allison J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med, 1995, Vol.182, no 2, pp. 459-65. [10.1084/jem.182.2.459] https://www.ncbi.nlm.nih.gov/pubmed/7543139Test; Laudanski P., Rogalska G., Warzecha D., Lipa M., Manka G., Kiecka M., Spaczynski R., Piekarski P., Banaszewska B., Jakimiuk A., Issat T., Rokita W., Mlodawski J., Szubert M., Sieroszewski P., Raba G., Szczupak K., Kluz T., Kluza M., Neuman T., Adler P., Peterson H., Salumets A.,Wielgos M. Autoantibody screening of plasma and peritoneal fluid of patients with endometriosis. Hum Reprod, 2023, Vol.38, no 4, pp. 629-643. [10.1093/humrep/dead011] https://www.ncbi.nlm.nih.gov/pubmed/36749097Test; Lee M.Y., Kim S.H., Oh Y.S., Heo S.H., Kim K.H., Chae H.D., Kim C.H.,Kang B.M. Role of interleukin-32 in the pathogenesis of endometriosis: in vitro, human and transgenic mouse data. Hum Reprod, 2018, Vol.33, no 5, pp. 807-816. [10.1093/humrep/dey055] https://www.ncbi.nlm.nih.gov/pubmed/29562285Test; Li C., Zhou J., Shao J., Yuan L., Cheng Q., Wang L.,Duan Z. Decrease in CD226 expression on CD4(+) T cells in patients with endometriosis. Biosci Trends, 2023, Vol.17, no 2, pp. 168-171. [10.5582/bst.2022.01501] https://www.ncbi.nlm.nih.gov/pubmed/37081668Test; Li J., Yan S., Li Q., Huang Y., Ji M., Jiao X., Yuan M.,Wang G. Macrophage-associated immune checkpoint CD47 blocking ameliorates endometriosis. Mol Hum Reprod, 2022, Vol.28, no 5. [10.1093/molehr/gaac010] https://www.ncbi.nlm.nih.gov/pubmed/35404426Test; Li Y., Zhang J., Zhang D., Hong X., Tao Y., Wang S., Xu Y., Piao H., Yin W., Yu M., Zhang Y., Fu Q., Li D., Chang X.,Du M. Tim-3 signaling in peripheral NK cells promotes maternal-fetal immune tolerance and alleviates pregnancy loss. Sci Signal, 2017, Vol.10, no 498. [10.1126/scisignal.aah4323] https://www.ncbi.nlm.nih.gov/pubmed/28951537Test; Liu Q., Ma P., Liu L., Ma G., Ma J., Liu X., Liu Y., Lin W.,Zhu Y. Evaluation of PLGA containing anti-CTLA4 inhibited endometriosis progression by regulating CD4+CD25+Treg cells in peritoneal fluid of mouse endometriosis model. Eur J Pharm Sci, 2017, Vol.96, no, pp. 542-550. [10.1016/j.ejps.2016.10.031] https://www.ncbi.nlm.nih.gov/pubmed/27989857Test; Lozano E., Dominguez-Villar M., Kuchroo V.,Hafler D.A. The TIGIT/CD226 axis regulates human T cell function. J Immunol, 2012, Vol.188, no 8, pp. 3869-75. [10.4049/jimmunol.1103627] https://www.ncbi.nlm.nih.gov/pubmed/22427644Test; Mahnke K.,Enk A.H. TIGIT-CD155 Interactions in Melanoma: A Novel Co-Inhibitory Pathway with Potential for Clinical Intervention. J Invest Dermatol, 2016, Vol.136, no 1, pp. 9-11. [10.1016/j.jid.2015.10.048] https://www.ncbi.nlm.nih.gov/pubmed/26763417Test; Man Y., Dai C., Guo Q., Jiang L.,Shi Y. A novel PD-1/PD-L1 pathway molecular typing-related signature for predicting prognosis and the tumor microenvironment in breast cancer. Discov Oncol, 2023, Vol.14, no 1, pp. 59. [10.1007/s12672-023-00669-4] https://www.ncbi.nlm.nih.gov/pubmed/37154982Test; Martin-Liberal J., Kordbacheh T.,Larkin J. Safety of pembrolizumab for the treatment of melanoma. Expert Opin Drug Saf, 2015, Vol.14, no 6, pp. 957-64. [10.1517/14740338.2015.1021774] https://www.ncbi.nlm.nih.gov/pubmed/25927979Test; Martire F.G., Russo C., Selntigia A., Nocita E., Soreca G., Lazzeri L., Zupi E.,Exacoustos C. Early noninvasive diagnosis of endometriosis: dysmenorrhea and specific ultrasound findings are important indicators in young women. Fertil Steril, 2023, Vol.119, no 3, pp. 455-464. [10.1016/j.fertnstert.2022.12.004] https://www.ncbi.nlm.nih.gov/pubmed/36493871Test; Maruhashi T., Sugiura D., Okazaki I.M.,Okazaki T. LAG-3: from molecular functions to clinical applications. J Immunother Cancer, 2020, Vol.8, no 2. [10.1136/jitc-2020-001014] https://www.ncbi.nlm.nih.gov/pubmed/32929051Test; Matalliotakis I., Neonaki M., Zolindaki A., Hassan E., Georgoulias V.,Koumantakis E. Changes in immunologic variables (TNF-a, sCD8 and sCD4) during danazol treatment in patients with endometriosis. Int J Fertil Womens Med, 1997, Vol.42, no 3, pp. 211-4. https://www.ncbi.nlm.nih.gov/pubmed/9222806Test; Matsubara E., Shinchi Y., Komohara Y., Yano H., Pan C., Fujiwara Y., Ikeda K.,Suzuki M. PD-L2 overexpression on tumor-associated macrophages is one of the predictors for better prognosis in lung adenocarcinoma. Med Mol Morphol, 2023 no. [10.1007/s00795-023-00361-0] https://www.ncbi.nlm.nih.gov/pubmed/37402054Test; Meggyes M., Szereday L., Bohonyi N., Koppan M., Szegedi S., Marics-Kutas A., Marton M., Totsimon A.,Polgar B. Different Expression Pattern of TIM-3 and Galectin-9 Molecules by Peripheral and Peritoneal Lymphocytes in Women with and without Endometriosis. Int J Mol Sci, 2020, Vol.21, no 7. [10.3390/ijms21072343] https://www.ncbi.nlm.nih.gov/pubmed/32231038Test; https://mdpi-res.com/d_attachment/ijms/ijms-21-02343/article_deploy/ijms-21-02343-v2.pdf?version=1585549834Test; Mikus M., Goldstajn M.S., Brlecic I., Dumancic S., Lagana A.S., Chiantera V., Vujic G.,Coric M. CTLA4-Linked Autoimmunity in the Pathogenesis of Endometriosis and Related Infertility: A Systematic Review. Int J Mol Sci, 2022, Vol.23, no 18. [10.3390/ijms231810902] https://www.ncbi.nlm.nih.gov/pubmed/36142815Test; Motamedi M., Shahbaz S., Fu L., Dunsmore G., Xu L., Harrington R., Houston S.,Elahi S. Galectin-9 Expression Defines a Subpopulation of NK Cells with Impaired Cytotoxic Effector Molecules but Enhanced IFN-gamma Production, Dichotomous to TIGIT, in HIV-1 Infection. Immunohorizons, 2019, Vol.3, no 11, pp. 531-546. [10.4049/immunohorizons.1900087] https://www.ncbi.nlm.nih.gov/pubmed/31732662Test; Muharam R., Bustami A., Gusti Mansur I., Zulkifli Jacoeb T., Giustiniani J., Schiavon V.,Bensussan A. Cytotoxic activity of peripheral blood mononuclear cells in patients with endometriosis: A cross-sectional study. Int J Reprod Biomed, 2022, Vol.20, no 8, pp. 691-700. [10.18502/ijrm.v20i8.11758] https://www.ncbi.nlm.nih.gov/pubmed/36313261Test; Murakami D., Matsuda K., Iwamoto H., Mitani Y., Mizumoto Y., Nakamura Y., Matsuzaki I., Iwamoto R., Takahashi Y., Kojima F., Murata S.I.,Yamaue H. Prognostic value of CD155/TIGIT expression in patients with colorectal cancer. PLoS One, 2022, Vol.17, no 3, pp. e0265908. [10.1371/journal.pone.0265908] https://www.ncbi.nlm.nih.gov/pubmed/35324958Test; Mutti L., Valle M.T., Balbi B., Orengo A.M., Lazzaro A., Alciato P., Gatti E., Betta P.G.,Pozzi E. Primary human mesothelioma cells express class II MHC, ICAM-1 and B7-2 and can present recall antigens to autologous blood lymphocytes. Int J Cancer, 1998, Vol.78, no 6, pp. 740-9. [10.1002/(sici)1097-0215(19981209)78:63.0.co;2-5] https://www.ncbi.nlm.nih.gov/pubmed/9833768Test; Naseri S., Rosenberg-Hasson Y., Maecker H.T., Avrutsky M.I.,Blumenthal P.D. A cross-sectional study comparing the inflammatory profile of menstrual effluent vs. peripheral blood. Health Sci Rep, 2023, Vol.6, no 1, pp. e1038. [10.1002/hsr2.1038] https://www.ncbi.nlm.nih.gov/pubmed/36620506Test; Nasr S., Haddad F.G., Khazen J., Kattan J.,Trak-Smayra V. PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: a single institution experience. BMC Cancer, 2023, Vol.23, no 1, pp. 817. [10.1186/s12885-023-11299-y] https://www.ncbi.nlm.nih.gov/pubmed/37658290Test; Neumann M., Murphy N.,Seetharamu N. The Evolving Role of PD-L1 Inhibition in Non-Small Cell Lung Cancer: A Review of Durvalumab and Avelumab. Cancer Med J, 2022, Vol.5, no 1, pp. 31-45. https://www.ncbi.nlm.nih.gov/pubmed/35253011Test; Nomi T., Sho M., Akahori T., Hamada K., Kubo A., Kanehiro H., Nakamura S., Enomoto K., Yagita H., Azuma M.,Nakajima Y. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res, 2007, Vol.13, no 7, pp. 2151-7. [10.1158/1078-0432.CCR-06-2746] https://www.ncbi.nlm.nih.gov/pubmed/17404099Test; Oksasoglu B., Hepokur C., Misir S., Yildiz C., Sonmez G.,Yanik A. Determination of PD-1 expression in peripheral blood cells in patients with endometriosis. Gynecol Endocrinol, 2021, Vol.37, no 2, pp. 157-161. [10.1080/09513590.2020.1821358] https://www.ncbi.nlm.nih.gov/pubmed/33078970Test; Olkowska-Truchanowicz J., Bialoszewska A., Zwierzchowska A., Sztokfisz-Ignasiak A., Janiuk I., Dabrowski F., Korczak-Kowalska G., Barcz E., Bocian K.,Malejczyk J. Peritoneal Fluid from Patients with Ovarian Endometriosis Displays Immunosuppressive Potential and Stimulates Th2 Response. Int J Mol Sci, 2021, Vol.22, no 15. [10.3390/ijms22158134] https://www.ncbi.nlm.nih.gov/pubmed/34360900Test; Ortiz C.N., Torres-Reveron A.,Appleyard C.B. Metabolomics in endometriosis: challenges and perspectives for future studies. Reprod Fertil, 2021, Vol.2, no 2, pp. R35-R50. [10.1530/RAF-20-0047] https://www.ncbi.nlm.nih.gov/pubmed/35128453Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812441/pdf/RAF-20-0047.pdfTest; Othman Eel D., Hornung D., Salem H.T., Khalifa E.A., El-Metwally T.H.,Al-Hendy A. Serum cytokines as biomarkers for nonsurgical prediction of endometriosis. Eur J Obstet Gynecol Reprod Biol, 2008, Vol.137, no 2, pp. 240-6. [10.1016/j.ejogrb.2007.05.001] https://www.ncbi.nlm.nih.gov/pubmed/17582674Test; Othman E.R., Hornung D., Hussein M., Abdelaal, II, Sayed A.A., Fetih A.N.,Al-Hendy A. Soluble tumor necrosis factor-alpha receptors in the serum of endometriosis patients. Eur J Obstet Gynecol Reprod Biol, 2016, Vol.200, no, pp. 1-5. [10.1016/j.ejogrb.2016.02.025] https://www.ncbi.nlm.nih.gov/pubmed/26963895Test; Oyama R., Kanayama M., Mori M., Matsumiya H., Taira A., Shinohara S., Takenaka M., Yoneda K., Kuroda K.,Tanaka F. CD155 expression and its clinical significance in non-small cell lung cancer. Oncol Lett, 2022, Vol.23, no 5, pp. 166. [10.3892/ol.2022.13286] https://www.ncbi.nlm.nih.gov/pubmed/35414831Test; Pan H.Y.,Wan J. Serum HSF1 is upregulated in endometriosis patients and serves as a potential diagnostic biomarker. Kaohsiung J Med Sci, 2023, Vol.39, no 10, pp. 1045-1051. [10.1002/kjm2.12723] https://www.ncbi.nlm.nih.gov/pubmed/37409787Test; Popovici R.M., Krause M.S., Germeyer A., Strowitzki T.,von Wolff M. Galectin-9: a new endometrial epithelial marker for the mid- and late-secretory and decidual phases in humans. J Clin Endocrinol Metab, 2005, Vol.90, no 11, pp. 6170-6. [10.1210/jc.2004-2529] https://www.ncbi.nlm.nih.gov/pubmed/16105962Test; Qi H., Li Y., Liu X., Jiang Y., Li Z., Xu X., Zhang H.,Hu X. Tim-3 regulates the immunosuppressive function of decidual MDSCs via the Fyn-STAT3-C/EBPbeta pathway during Toxoplasma gondii infection. PLoS Pathog, 2023, Vol.19, no 4, pp. e1011329. [10.1371/journal.ppat.1011329] https://www.ncbi.nlm.nih.gov/pubmed/37058540Test; Raschi E., Comito F., Massari F.,Gelsomino F. Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY. Immunotherapy, 2023, Vol.15, no 2, pp. 85-91. [10.2217/imt-2022-0172] https://www.ncbi.nlm.nih.gov/pubmed/36628573Test; Rondon L., Fu R.,Patel M.R. Success of Checkpoint Blockade Paves the Way for Novel Immune Therapy in Malignant Pleural Mesothelioma. Cancers (Basel), 2023, Vol.15, no 11. [10.3390/cancers15112940] https://www.ncbi.nlm.nih.gov/pubmed/37296902Test; Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res, 2019, Vol.38, no 1, pp. 255. [10.1186/s13046-019-1259-z] https://www.ncbi.nlm.nih.gov/pubmed/31196207Test; Sansone A.M., Hisrich B.V., Young R.B., Abel W.F., Bowens Z., Blair B.B., Funkhouser A.T., Schammel D.P., Green L.J., Lessey B.A.,Blenda A.V. Evaluation of BCL6 and SIRT1 as Non-Invasive Diagnostic Markers of Endometriosis. Curr Issues Mol Biol, 2021, Vol.43, no 3, pp. 1350-1360. [10.3390/cimb43030096] https://www.ncbi.nlm.nih.gov/pubmed/34698105Test; Santoso B., Sa'adi A., Dwiningsih S.R., Tunjungseto A., Widyanugraha M.Y.A., Mufid A.F., Rahmawati N.Y.,Ahsan F. Soluble immune checkpoints CTLA-4, HLA-G, PD-1, and PD-L1 are associated with endometriosis-related infertility. Am J Reprod Immunol, 2020, Vol.84, no 4, pp. e13296. [10.1111/aji.13296] https://www.ncbi.nlm.nih.gov/pubmed/32593225Test; Shafrir A.L., Farland L.V., Shah D.K., Harris H.R., Kvaskoff M., Zondervan K.,Missmer S.A. Risk for and consequences of endometriosis: A critical epidemiologic review. Best Pract Res Clin Obstet Gynaecol, 2018, Vol.51, no, pp. 1-15. [10.1016/j.bpobgyn.2018.06.001] https://www.ncbi.nlm.nih.gov/pubmed/30017581Test; Shah M., Osgood C.L., Amatya A.K., Fiero M.H., Pierce W.F., Nair A., Herz J., Robertson K.J., Mixter B.D., Tang S., Pazdur R., Beaver J.A.,Amiri-Kordestani L. FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer. Clin Cancer Res, 2022, Vol.28, no 24, pp. 5249-5253. [10.1158/1078-0432.CCR-22-1110] https://www.ncbi.nlm.nih.gov/pubmed/35925043Test; Shigesi N., Kvaskoff M., Kirtley S., Feng Q., Fang H., Knight J.C., Missmer S.A., Rahmioglu N., Zondervan K.T.,Becker C.M. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis. Hum Reprod Update, 2019, Vol.25, no 4, pp. 486-503. [10.1093/humupd/dmz014] https://www.ncbi.nlm.nih.gov/pubmed/31260048Test; Simone R., Pesce G., Antola P., Rumbullaku M., Bagnasco M., Bizzaro N.,Saverino D. The soluble form of CTLA-4 from serum of patients with autoimmune diseases regulates T-cell responses. Biomed Res Int, 2014, Vol.2014, no, pp. 215763. [10.1155/2014/215763] https://www.ncbi.nlm.nih.gov/pubmed/24605322Test; Souza D.S., Macheroni C., Pereira G.J.S., Vicente C.M.,Porto C.S. Molecular regulation of prostate cancer by Galectin-3 and estrogen receptor. Front Endocrinol (Lausanne), 2023, Vol.14, no, pp. 1124111. [10.3389/fendo.2023.1124111] https://www.ncbi.nlm.nih.gov/pubmed/36936148Test; Stanietsky N., Simic H., Arapovic J., Toporik A., Levy O., Novik A., Levine Z., Beiman M., Dassa L., Achdout H., Stern-Ginossar N., Tsukerman P., Jonjic S.,Mandelboim O. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A, 2009, Vol.106, no 42, pp. 17858-63. [10.1073/pnas.0903474106] https://www.ncbi.nlm.nih.gov/pubmed/19815499Test; Stasenko M., Smith E., Yeku O., Park K.J., Laster I., Lee K., Walderich S., Spriggs E., Rueda B., Weigelt B., Zamarin D., Rao T.D.,Spriggs D.R. Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies. Sci Rep, 2021, Vol.11, no 1, pp. 3718. [10.1038/s41598-021-82686-3] https://www.ncbi.nlm.nih.gov/pubmed/33580170Test; Suszczyk D., Skiba W., Zardzewialy W., Pawlowska A., Wlodarczyk K., Polak G., Tarkowski R.,Wertel I. Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis. Int J Mol Sci, 2022, Vol.23, no 19. [10.3390/ijms231911607] https://www.ncbi.nlm.nih.gov/pubmed/36232911Test; https://mdpi-res.com/d_attachment/ijms/ijms-23-11607/article_deploy/ijms-23-11607-v2.pdf?version=1665309498Test; Suzman D.L., Agrawal S., Ning Y.M., Maher V.E., Fernandes L.L., Karuri S., Tang S., Sridhara R., Schroeder J., Goldberg K.B., Ibrahim A., McKee A.E., Pazdur R.,Beaver J.A. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy. Oncologist, 2019, Vol.24, no 4, pp. 563-569. [10.1634/theoncologist.2018-0084] https://www.ncbi.nlm.nih.gov/pubmed/30541754Test; Sznol M. Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy. Cancer J, 2014, Vol.20, no 4, pp. 290-5. [10.1097/PPO.0000000000000056] https://www.ncbi.nlm.nih.gov/pubmed/25098290Test; Tahermanesh K., Hakimpour S., Govahi A., Rokhgireh S., Mehdizadeh M., Minaeian S., Barati M., Chaichian S., Kashi A.M., Nassiri S., Eslahi N., Ajdary M.,Ahmadi M. Evaluation of expression of biomarkers of PLAGL1 (ZAC1), microRNA, and their non-coding RNAs in patients with endometriosis. J Gynecol Obstet Hum Reprod, 2023, Vol.52, no 4, pp. 102568. [10.1016/j.jogoh.2023.102568] https://www.ncbi.nlm.nih.gov/pubmed/36868502Test; Tanaka E., Sendo F., Kawagoe S.,Hiroi M. Decreased natural killer cell activity in women with endometriosis. Gynecol Obstet Invest, 1992, Vol.34, no 1, pp. 27-30. [10.1159/000292720] https://www.ncbi.nlm.nih.gov/pubmed/1526528Test; Tang T., Lai H., Huang X., Gu L.,Shi H. Application of serum markers in diagnosis and staging of ovarian endometriosis. J Obstet Gynaecol Res, 2021, Vol.47, no 4, pp. 1441-1450. [10.1111/jog.14654] https://www.ncbi.nlm.nih.gov/pubmed/33448139Test; Tella S.H., Kommalapati A., Mahipal A.,Jin Z. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination. Biomedicines, 2022, Vol.10, no 6. [10.3390/biomedicines10061304] https://www.ncbi.nlm.nih.gov/pubmed/35740326Test; Timmerman J., Herbaux C., Ribrag V., Zelenetz A.D., Houot R., Neelapu S.S., Logan T., Lossos I.S., Urba W., Salles G., Ramchandren R., Jacobson C., Godwin J., Carpio C., Lathers D., Liu Y., Neely J., Suryawanshi S., Koguchi Y.,Levy R. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. Am J Hematol, 2020, Vol.95, no 5, pp. 510-520. [10.1002/ajh.25757] https://www.ncbi.nlm.nih.gov/pubmed/32052473Test; Vellanki P.J., Mulkey F., Jaigirdar A.A., Rodriguez L., Wang Y., Xu Y., Zhao H., Liu J., Howe G., Wang J., Choo Q., Golding S.J., Mansell V., Korsah K., Spillman D., de Claro R.A., Pazdur R., Beaver J.A.,Singh H. FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non-small Cell Lung Cancer, A Collaborative Project Orbis Review. Clin Cancer Res, 2021, Vol.27, no 13, pp. 3522-3527. [10.1158/1078-0432.CCR-20-4338] https://www.ncbi.nlm.nih.gov/pubmed/33632925Test; Vence L., Bucktrout S.L., Fernandez Curbelo I., Blando J., Smith B.M., Mahne A.E., Lin J.C., Park T., Pascua E., Sai T., Chaparro-Riggers J., Subudhi S.K., Scutti J.B., Higa M.G., Zhao H., Yadav S.S., Maitra A., Wistuba, II, Allison J.P.,Sharma P. Characterization and Comparison of GITR Expression in Solid Tumors. Clin Cancer Res, 2019, Vol.25, no 21, pp. 6501-6510. [10.1158/1078-0432.CCR-19-0289] https://www.ncbi.nlm.nih.gov/pubmed/31358539Test; Villanacci R., Bandini V., Ottolina J., Pagliardini L., Candiani M.,Vigano P. The pathogenesis of endometriosis: clues from the immunological evidence. Minerva Obstet Gynecol, 2021, Vol.73, no 3, pp. 275-282. [10.23736/S2724-606X.21.04768-7] https://www.ncbi.nlm.nih.gov/pubmed/34008382Test; Vinay D.S.,Kwon B.S. 4-1BB signaling beyond T cells. Cell Mol Immunol, 2011, Vol.8, no 4, pp. 281-4. [10.1038/cmi.2010.82] http://www.ncbi.nlm.nih.gov/pubmed/21217771Test; http://www.nature.com/cmi/journal/v8/n4/pdf/cmi201082a.pdfTest; von Euw E., Chodon T., Attar N., Jalil J., Koya R.C., Comin-Anduix B.,Ribas A. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med, 2009, Vol.7, no, pp. 35. [10.1186/1479-5876-7-35] https://www.ncbi.nlm.nih.gov/pubmed/19457253Test; Walankiewicz M., Grywalska E., Polak G., Korona-Glowniak I., Witt E., Surdacka A., Kotarski J.,Rolinski J. The Increase of Circulating PD-1- and PD-L1-Expressing Lymphocytes in Endometriosis: Correlation with Clinical and Laboratory Parameters. Mediators Inflamm, 2018, Vol.2018, no, pp. 7041342. [10.1155/2018/7041342] https://www.ncbi.nlm.nih.gov/pubmed/30595667Test; Wang X.B., Fan Z.Z., Anton D., Vollenhoven A.V., Ni Z.H., Chen X.F.,Lefvert A.K. CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation. BMC Immunol, 2011, Vol.12, no, pp. 21. [10.1186/1471-2172-12-21] https://www.ncbi.nlm.nih.gov/pubmed/21414236Test; Wang Y., Du J., Gao Z., Sun H., Mei M., Wang Y., Ren Y.,Zhou X. Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy. Br J Cancer, 2023, Vol.128, no 7, pp. 1196-1207. [10.1038/s41416-022-02084-y] https://www.ncbi.nlm.nih.gov/pubmed/36522474Test; Wang Y., Feng T., Li H., Xiong Y.,Tao Y. Gal-9/Tim-3 signaling pathway activation suppresses the generation of Th17 cells and promotes the induction of Foxp3(+) regulatory T cells in renal ischemia-reperfusion injury. Mol Immunol, 2023, Vol.156, no, pp. 136-147. [10.1016/j.molimm.2023.03.008] https://www.ncbi.nlm.nih.gov/pubmed/36921488Test; Warzecha D., Zalecka J., Manka G., Kiecka M., Lipa M., Spaczynski R., Piekarski P., Banaszewska B., Jakimiuk A., Issat T., Rokita W., Mlodawski J., Szubert M., Sieroszewski P., Raba G., Szczupak K., Kluz T., Kluza M., Wielgos M., Oldak L., Lesniewska A., Gorodkiewicz E.,Laudanski P. Plasma and Peritoneal Fluid Fibronectin and Collagen IV Levels as Potential Biomarkers of Endometriosis. Int J Mol Sci, 2022, Vol.23, no 24. [10.3390/ijms232415669] https://www.ncbi.nlm.nih.gov/pubmed/36555313Test; Wessels J.M., Kay V.R., Leyland N.A., Agarwal S.K.,Foster W.G. Assessing brain-derived neurotrophic factor as a novel clinical marker of endometriosis. Fertil Steril, 2016, Vol.105, no 1, pp. 119-28 e1-5. [10.1016/j.fertnstert.2015.09.003] https://www.ncbi.nlm.nih.gov/pubmed/26409150Test; Wiles K.N., Tsikretsis L.E., Alioto C.M., Hermida de Viveiros P.A., Villaflor V.M.,Tetreault M.P. GITR agonistic stimulation enhances the anti-tumor immune response in a mouse model of ESCC. Carcinogenesis, 2022, Vol.43, no 9, pp. 908-918. [10.1093/carcin/bgac064] https://www.ncbi.nlm.nih.gov/pubmed/35880612Test; Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T., Miyara M., Fehervari Z., Nomura T.,Sakaguchi S. CTLA-4 control over Foxp3+ regulatory T cell function. Science, 2008, Vol.322, no 5899, pp. 271-5. [10.1126/science.1160062] http://www.ncbi.nlm.nih.gov/pubmed/18845758Test; Wroblewski J.M., Bixby D.L., Borowski C.,Yannelli J.R. Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens. Lung Cancer, 2001, Vol.33, no 2-3, pp. 181-94. [10.1016/s0169-5002(01)00210-0] https://www.ncbi.nlm.nih.gov/pubmed/11551413Test; Wu L., Lv C., Su Y., Li C., Zhang H., Zhao X.,Li M. Expression of programmed death-1 (PD-1) and its ligand PD-L1 is upregulated in endometriosis and promoted by 17beta-estradiol. Gynecol Endocrinol, 2019, Vol.35, no 3, pp. 251-256. [10.1080/09513590.2018.1519787] https://www.ncbi.nlm.nih.gov/pubmed/30325236Test; Xu F., Liu J., Liu D., Liu B., Wang M., Hu Z., Du X., Tang L.,He F. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. Cancer Res, 2014, Vol.74, no 13, pp. 3418-28. [10.1158/0008-5472.CAN-13-2690] https://www.ncbi.nlm.nih.gov/pubmed/24769443Test; Xu J.X., Maher V.E., Zhang L., Tang S., Sridhara R., Ibrahim A., Kim G.,Pazdur R. FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis. Oncologist, 2017, Vol.22, no 3, pp. 311-317. [10.1634/theoncologist.2016-0476] https://www.ncbi.nlm.nih.gov/pubmed/28232599Test; Xue C., Zhu D., Chen L., Xu Y., Xu B., Zhang D.,Jiang J. Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer. Transl Cancer Res, 2019, Vol.8, no 1, pp. 111-119. [10.21037/tcr.2019.01.09] https://www.ncbi.nlm.nih.gov/pubmed/35116740Test; Yamashita S., Hashimoto K., Sawada I., Ogawa M., Nakatsuka E., Kawano M., Kinose Y., Kodama M., Sawada K.,Kimura T. Endometrial galectin-3 causes endometriosis by supporting eutopic endometrial cell survival and engraftment in the peritoneal cavity. Am J Reprod Immunol, 2022, Vol.87, no 6, pp. e13533. [10.1111/aji.13533] https://www.ncbi.nlm.nih.gov/pubmed/35366371Test; Yan J., Zhang Y., Zhang J.P., Liang J., Li L.,Zheng L. Tim-3 expression defines regulatory T cells in human tumors. PLoS One, 2013, Vol.8, no 3, pp. e58006. [10.1371/journal.pone.0058006] https://www.ncbi.nlm.nih.gov/pubmed/23526963Test; Yang M., Yu Q., Liu J., Fu W., Cao Y., Yu L., Shao S., Wang X., Niu H.,Wang Y. T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival. J Surg Oncol, 2015, Vol.112, no 4, pp. 430-5. [10.1002/jso.24012] https://www.ncbi.nlm.nih.gov/pubmed/26265374Test; Yasinska I.M., Sakhnevych S.S., Pavlova L., Teo Hansen Selno A., Teuscher Abeleira A.M., Benlaouer O., Goncalves Silva I., Mosimann M., Varani L., Bardelli M., Hussain R., Siligardi G., Cholewa D., Berger S.M., Gibbs B.F., Ushkaryov Y.A., Fasler-Kan E., Klenova E.,Sumbayev V.V. The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer. Front Immunol, 2019, Vol.10, no, pp. 1594. [10.3389/fimmu.2019.01594] https://www.ncbi.nlm.nih.gov/pubmed/31354733Test; Yildiz C., Caner A., Oksasoglu B., Misir S., Yaylim I.,Hepokur C. The role of cytokeratin 19 levels in the determination of endometriosis stages. Gynecol Endocrinol, 2022, Vol.38, no 10, pp. 879-884. [10.1080/09513590.2022.2120606] https://www.ncbi.nlm.nih.gov/pubmed/36068968Test; Zhang C., Xu L., Ma Y., Huang Y., Zhou L., Le H.,Chen Z. Increased TIM-3 expression in tumor-associated macrophages predicts a poorer prognosis in non-small cell lung cancer: a retrospective cohort study. J Thorac Dis, 2023, Vol.15, no 3, pp. 1433-1444. [10.21037/jtd-23-227] https://www.ncbi.nlm.nih.gov/pubmed/37065598Test; Zhang Y., Wu L., Wen X.,Lv X. Identification and validation of risk score model based on gene set activity as a diagnostic biomarker for endometriosis. Heliyon, 2023, Vol.9, no 7, pp. e18277. [10.1016/j.heliyon.2023.e18277] https://www.ncbi.nlm.nih.gov/pubmed/37539146Test; Zhang Y., Yang R., Xu C., Zhang Y., Deng M., Wu D., Tang F., Liu X., Han Y., Zhan Y.,Miao J. Analysis of the immune checkpoint lymphocyte activation gene-3 (LAG-3) in endometrial cancer: An emerging target for immunotherapy. Pathol Res Pract, 2022, Vol.236, no, pp. 153990. [10.1016/j.prp.2022.153990] https://www.ncbi.nlm.nih.gov/pubmed/35749914Test; Zhang Y., Yao Q., Pan Y., Fang X., Xu H., Zhao T., Zhu G., Jiang T., Li S.,Cao H. Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review. Cancers (Basel), 2023, Vol.15, no 3. [10.3390/cancers15030682] https://www.ncbi.nlm.nih.gov/pubmed/36765640Test; Zhang Y., Zhang H., Wei M., Mou T., Shi T., Ma Y., Cai X., Li Y., Dong J.,Wei J. Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8(+) T Cells in HCC. Mol Ther, 2019, Vol.27, no 11, pp. 1906-1918. [10.1016/j.ymthe.2019.07.019] https://www.ncbi.nlm.nih.gov/pubmed/31466933Test; Zhang Y.,Zheng J. Functions of Immune Checkpoint Molecules Beyond Immune Evasion. Adv Exp Med Biol, 2020, Vol.1248, no, pp. 201-226. [10.1007/978-981-15-3266-5_9] https://www.ncbi.nlm.nih.gov/pubmed/32185712Test; Zheng D., Hou X., Yu J.,He X. Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes. Front Pharmacol, 2022, Vol.13, no, pp. 928369. [10.3389/fphar.2022.928369] https://www.ncbi.nlm.nih.gov/pubmed/35935874Test; Zheng L., Sun D.F.,Tong Y. Exosomal miR-202 derived from leukorrhea as a potential biomarker for endometriosis. J Int Med Res, 2023, Vol.51, no 1, pp. 3000605221147183. [10.1177/03000605221147183] https://www.ncbi.nlm.nih.gov/pubmed/36597409Test; Zhou E., Huang Q., Wang J., Fang C., Yang L., Zhu M., Chen J., Chen L.,Dong M. Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer. Int J Clin Exp Pathol, 2015, Vol.8, no 7, pp. 8018-27. https://www.ncbi.nlm.nih.gov/pubmed/26339368Test; Zhu C., Anderson A.C., Schubart A., Xiong H., Imitola J., Khoury S.J., Zheng X.X., Strom T.B.,Kuchroo V.K. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol, 2005, Vol.6, no 12, pp. 1245-52. [10.1038/ni1271] https://www.ncbi.nlm.nih.gov/pubmed/16286920Test; Zhu H., Wang M., Du Y., Liu X., Weng X.,Li C. 4-1BBL has a Possible Role in Mediating Castration-Resistant Conversion of Prostate Cancer via Up-Regulation of Androgen Receptor. J Cancer, 2019, Vol.10, no 11, pp. 2464-2471. [10.7150/jca.29648] https://www.ncbi.nlm.nih.gov/pubmed/31258752Test; Ziogas I.A., Evangeliou A.P., Giannis D., Hayat M.H., Mylonas K.S., Tohme S., Geller D.A., Elias N., Goyal L.,Tsoulfas G. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients. Oncologist, 2021, Vol.26, no 6, pp. e1036-e1049. [10.1002/onco.13638] https://www.ncbi.nlm.nih.gov/pubmed/33314549Test; https://www.mimmun.ru/mimmun/article/view/2923Test

الإتاحة: https://doi.org/10.15789/1563-0625-CIT-2923Test
https://doi.org/10.15789/1563-0625-0-0Test
https://www.mimmun.ru/mimmun/article/view/2923Test

View record in BASE

4

دورية أكاديمية

MODERN WAYS TO OVERCOME ANTIBIOTIC RESISTANCE AND PROSPECTS FOR THE USE OF NK CELLS AS AGENTS OF ANTIBACTERIAL THERAPY ; СОВРЕМЕННЫЕ СПОСОБЫ ПРЕОДОЛЕНИЯ АНТИБИОТИКОРЕЗИСТЕНТНОСТИ И ПЕРСПЕКТИВЫ ИСПОЛЬЗОВАНИЯ NK-КЛЕТОК КАК АГЕНТОВ АНТИБАКТЕРИАЛЬНОЙ ТЕРАПИИ

المؤلفون: Polina Vladimirovna Grebenkina, Varvara Alekseevna Jukhina, Ananstasia Maksimovna Gulina, Sergey Alekseevich Selkov, Lyudmila Alexandrovna Kraeva, Dmitriy Igorevich Sokolov, Полина Владимировна Гребенкина, Варвара Алексеевна Юхина, Анастасия Максимовна Гулина, Сергей Алексеевич Сельков, Людмила Александровна Краева, Дмитрий Игоревич Соколов

المصدر: Medical Immunology (Russia); Online First ; Медицинская иммунология; Online First ; 2313-741X ; 1563-0625 ; 10.15789/1563-0625-0-0

مصطلحات موضوعية: устойчивость, antibiotics, ESKAPE, microvesicles, bacteria, resistance, антибиотики, микровезикулы, бактерии

وصف الملف: application/pdf

العلاقة: https://www.mimmun.ru/mimmun/article/view/2945/1928Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2945/13321Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2945/13322Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2945/13323Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2945/13324Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2945/13325Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2945/13326Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2945/13475Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2945/13476Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2945/13477Test; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2945/13569Test; Abraham E.P.,Chain E. An enzyme from bacteria able to destroy penicillin. 1940. Rev Infect Dis, 1988, Vol.10, no 4, pp. 677-8. -; Ananthan S.,Subha A. Cefoxitin Resistance Mediated by Loss of a Porin in Clinical Strains of Klebsiella Pneumoniae and Escherichia Coli. Indian Journal of Medical Microbiology, 2005, Vol.23, no 1, pp. 20-23. - 10.1016/s0255-0857(21)02706-7; Anderl J.N., Franklin M.J.,Stewart P.S. Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother, 2000, Vol.44, no 7, pp. 1818-24. - 10.1128/AAC.44.7.1818-1824.2000; Ayobami O., Brinkwirth S., Eckmanns T.,Markwart R. Antibiotic resistance in hospital-acquired ESKAPE-E infections in low- and lower-middle-income countries: a systematic review and meta-analysis. Emerging Microbes & Infections, 2022, Vol.11, no 1, pp. 443-451. - 10.1080/22221751.2022.2030196; Azevedo-Barbosa H., Dias D.F., Franco L.L., Hawkes J.A.,Carvalho D.T. From Antibacterial to Antitumour Agents: A Brief Review on The Chemical and Medicinal Aspects of Sulfonamides. Mini Rev Med Chem, 2020, Vol.20, no 19, pp. 2052-2066. - 10.2174/1389557520666200905125738; Baroud M., Dandache I., Araj G.F., Wakim R., Kanj S., Kanafani Z., Khairallah M., Sabra A., Shehab M., Dbaibo G.,Matar G.M. Underlying mechanisms of carbapenem resistance in extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli isolates at a tertiary care centre in Lebanon: role of OXA-48 and NDM-1 carbapenemases. Int J Antimicrob Agents, 2013, Vol.41, no 1, pp. 75-9. - 10.1016/j.ijantimicag.2012.08.010; Baumler A.J., Ivin M., Dumigan A., de Vasconcelos F.N., Ebner F., Borroni M., Kavirayani A., Przybyszewska K.N., Ingram R.J., Lienenklaus S., Kalinke U., Stoiber D., Bengoechea J.A.,Kovarik P. Natural killer cell-intrinsic type I IFN signaling controls Klebsiella pneumoniae growth during lung infection. PLOS Pathogens, 2017, Vol.13, no 11. - 10.1371/journal.ppat.1006696; Bhattacharjee M.K., Antimetabolites: Antibiotics That Inhibit Nucleotide Synthesis, in Chemistry of Antibiotics and Related Drugs. 2022. p. 109-123. -; Binda E., Marinelli F.,Marcone G.L. Old and New Glycopeptide Antibiotics: Action and Resistance. Antibiotics (Basel), 2014, Vol.3, no 4, pp. 572-94. - 10.3390/antibiotics3040572; Bisacchi G.,Hale M. A “Double-Edged” Scaffold: Antitumor Power within the Antibacterial Quinolone. Current Medicinal Chemistry, 2016, Vol.23, no 6, pp. 520-577. - 10.2174/0929867323666151223095839; Bisacchi G.S. Origins of the Quinolone Class of Antibacterials: An Expanded "Discovery Story". J Med Chem, 2015, Vol.58, no 12, pp. 4874-82. - 10.1021/jm501881c; Blair J.M.A., Webber M.A., Baylay A.J., Ogbolu D.O.,Piddock L.J.V. Molecular mechanisms of antibiotic resistance. Nature Reviews Microbiology, 2014, Vol.13, no 1, pp. 42-51. - 10.1038/nrmicro3380; Blake F.G.,Craige B. Penicillin in Suppurative Disease of the Lungs: A Report of Three Cases. Yale J Biol Med, 1943, Vol.15, no 3, pp. 507-516 7.; Blaskovich M.A.T., Hansford K.A., Butler M.S., Jia Z., Mark A.E.,Cooper M.A. Developments in Glycopeptide Antibiotics. ACS Infect Dis, 2018, Vol.4, no 5, pp. 715-735. - 10.1021/acsinfecdis.7b00258; Bourne C.R. Utility of the Biosynthetic Folate Pathway for Targets in Antimicrobial Discovery. Antibiotics (Basel), 2014, Vol.3, no 1, pp. 1-28. - 10.3390/antibiotics3010001; Boyiadzis M., Agha M., Redner R.L., Sehgal A., Im A., Hou J.-Z., Farah R., Dorritie K.A., Raptis A., Lim S.H., Wang H., Lapteva N., Mei Z., Butterfield L.H., Rooney C.M.,Whiteside T.L. Phase 1 clinical trial of adoptive immunotherapy using “off-the-shelf” activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy, 2017, Vol.19, no 10, pp. 1225-1232. - 10.1016/j.jcyt.2017.07.008; Breijyeh Z., Jubeh B.,Karaman R. Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It. Molecules, 2020, Vol.25, no 6. - 10.3390/molecules25061340; Brockmann H.,Henkel W. Pikromycin, ein bitter schmeckendes Antibioticum aus Actinomyceten (Antibiotica aus Actinomyceten, VI. Mitteil. Chemische Berichte, 2006, Vol.84, no 3, pp. 284-288. - 10.1002/cber.19510840306; Brooks L.E., Ul-Hasan S., Chan B.K.,Sistrom M.J. Quantifying the Evolutionary Conservation of Genes Encoding Multidrug Efflux Pumps in the ESKAPE Pathogens To Identify Antimicrobial Drug Targets. mSystems, 2018, Vol.3. - 10.1128/mSystems.00024-18; Bryan L.E.,Kwan S. Roles of ribosomal binding, membrane potential, and electron transport in bacterial uptake of streptomycin and gentamicin. Antimicrob Agents Chemother, 1983, Vol.23, no 6, pp. 835-45. - 10.1128/AAC.23.6.835; Camussi G., Deregibus M.C., Bruno S., Cantaluppi V.,Biancone L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int, 2010, Vol.78, no 9, pp. 838-48. - 10.1038/ki.2010.278; Chalifour A., Jeannin P., Gauchat J.F., Blaecke A., Malissard M., N'Guyen T., Thieblemont N.,Delneste Y. Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers alpha-defensin production. Blood, 2004, Vol.104, no 6, pp. 1778-83. - 10.1182/blood-2003-08-2820; Chen N.,Jiang C. Antimicrobial peptides: Structure, mechanism, and modification. European Journal of Medicinal Chemistry, 2023, Vol.255, no. 7; 10.1016/j.ejmech.2023.11537; Comin F., Speziali E., Martins-Filho O.A., Caldas I.R., Moura V., Gazzinelli A., Correa-Oliveira R.,Faria A.M.C. Ageing and Toll-like receptor expression by innate immune cells in chronic human schistosomiasis. Clinical and Experimental Immunology, 2007, Vol.149, no 2, pp. 274-284. - 10.1111/j.1365-2249.2007.03403.x; Crespo Â.C., Mulik S., Dotiwala F., Ansara J.A., Sen Santara S., Ingersoll K., Ovies C., Junqueira C., Tilburgs T., Strominger J.L.,Lieberman J. Decidual NK Cells Transfer Granulysin to Selectively Kill Bacteria in Trophoblasts. Cell, 2020, Vol.182, no 5, pp. 1125-1139.e18. - 10.1016/j.cell.2020.07.019; Demerec M.,Fano U. Bacteriophage-Resistant Mutants in Escherichia Coli. Genetics, 1945, Vol.30, no 2, pp. 119-136. - 10.1093/genetics/30.2.119; Dinos G.P. The macrolide antibiotic renaissance. Br J Pharmacol, 2017, Vol.174, no 18, pp. 2967-2983. - 10.1111/bph.13936; El-Badawy M.F., Tawakol W.M., El-Far S.W., Maghrabi I.A., Al-Ghamdi S.A., Mansy M.S., Ashour M.S.,Shohayeb M.M. Molecular Identification of Aminoglycoside-Modifying Enzymes and Plasmid-Mediated Quinolone Resistance Genes among Klebsiella pneumoniae Clinical Isolates Recovered from Egyptian Patients. International Journal of Microbiology, 2017, Vol.2017, no, pp. 1-12. - 10.1155/2017/8050432; El-Sayed Ahmed M.A.E.-G., Zhong L.-L., Shen C., Yang Y., Doi Y.,Tian G.-B. Colistin and its role in the Era of antibiotic resistance: an extended review (2000–2019). Emerging Microbes & Infections, 2020, Vol.9, no 1, pp. 868-885. - 10.1080/22221751.2020.1754133; Emelianova A.G., Petrova N.V., Fremez C., Fontanié M., Tarasov S.А.,Epstein О.I. Therapeutic potential of highly diluted antibodies in antibiotic-resistant infection. European Journal of Pharmaceutical Sciences, 2022, Vol.173, no. - 10.1016/j.ejps.2022.106161; Eriksson M., Meadows S.K., Basu S., Mselle T.F., Wira C.R.,Sentman C.L. TLRs mediate IFN-gamma production by human uterine NK cells in endometrium. J Immunol, 2006, Vol.176, no 10, pp. 6219-24. - 10.4049/jimmunol.176.10.6219; Eyler R.F.,Shvets K. Clinical Pharmacology of Antibiotics. Clinical Journal of the American Society of Nephrology, 2019, Vol.14, no 7, pp. 1080-1090. - 10.2215/cjn.08140718; Fazly Bazzaz B.S., Khameneh B., Zarei H.,Golmohammadzadeh S. Antibacterial efficacy of rifampin loaded solid lipid nanoparticles against Staphylococcus epidermidis biofilm. Microbial Pathogenesis, 2016, Vol.93, no, pp. 137-144. - 10.1016/j.micpath.2015.11.031; Fernández-Martínez M., Ruiz del Castillo B., Lecea-Cuello M.J., Rodríguez-Baño J., Pascual Á., Martínez-Martínez L., Michaus L., Martínez Peinado C., Yagüe A., Torreblanca A., Fleites A., Ordás J.F., Moreno J.J., Garduño E., Gil J., Oliver A., Domínguez M.A., Marco F., del Valle O., Navarro F., Prats G., Corcoy F., Ojeda E., Marín P., Fernández C., Martínez L., Carranza R., Rodríguez F., García Tejero C., Artiles F., Álamo I., Palop B., De la Rosa M., Gutiérrez J., Gomáriz M., Cuesta I., Cartelle M., Rodríguez M., Fernández I., Ugalde E., Picazo J.J., Chaves F., Cantón R., Cercenado E., Folgueira L., Delgado Iribarren A., Guerrero C., Torroba L., García Irure J.J., Fernández B., García M., Lueiro F., Otero I., García Sánchez E., Elías J., Treviño M., Hernández J.R., Ruiz M., Díaz M.A., Moreno A., Lara M., Aspiroz C., Torres L., García Leoni E., Navarro D., Gobernado M., Tenorio A., Ezpeleta C., Castillo J.,García Moya J. Prevalence of Aminoglycoside-Modifying Enzymes in Escherichia coli and Klebsiella pneumoniae Producing Extended Spectrum β-Lactamases Collected in Two Multicenter Studies in Spain. Microbial Drug Resistance, 2018, Vol.24, no 4, pp. 367-376. - 10.1089/mdr.2017.0102; Ferreira M., Pinto S.N., Aires-da-Silva F., Bettencourt A., Aguiar S.I.,Gaspar M.M. Liposomes as a Nanoplatform to Improve the Delivery of Antibiotics into Staphylococcus aureus Biofilms. Pharmaceutics, 2021, Vol.13, no 3. - 10.3390/pharmaceutics13030321; Fleming A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. 1929. Bull World Health Organ, 2001, Vol.79, no 8, pp. 780-90. - 10.3390/molecules26144280; Foti C., Piperno A., Scala A.,Giuffrè O. Oxazolidinone Antibiotics: Chemical, Biological and Analytical Aspects. Molecules, 2021, Vol.26, no 14. -; Fouts J.R., Kamm J.J.,Brodie B.B. Enzymatic reduction of prontosil and other azo dyes. J Pharmacol Exp Ther, 1957, Vol.120, no 3, pp. 291-300. -; Gautier-Bouchardon A.V., Aarestrup F.M., Schwarz S., Shen J.,Cavaco L. Antimicrobial Resistance in; Mycoplasma; spp. Microbiology Spectrum, 2018, Vol.6, no 4. - 10.1128/microbiolspec.ARBA-0030-2018; Geigenmuller U.,Nierhaus K.H. Tetracycline can inhibit tRNA binding to the ribosomal P site as well as to the A site. Eur J Biochem, 1986, Vol.161, no 3, pp. 723-6. - 10.1111/j.1432-1033.1986.tb10499.x; González-Paredes A., Sitia L., Ruyra A., Morris C.J., Wheeler G.N., McArthur M.,Gasco P. Solid lipid nanoparticles for the delivery of anti-microbial oligonucleotides. European Journal of Pharmaceutics and Biopharmaceutics, 2019, Vol.134, no, pp. 166-177. - 10.1016/j.ejpb.2018.11.017; Hahn A., Sami I., Chaney H., Koumbourlis A.C., Del Valle Mojica C., Cochrane C., Chan B.K.,Koff J.L. Bacteriophage Therapy for Pan-Drug-Resistant Pseudomonas aeruginosa in Two Persons With Cystic Fibrosis. Journal of Investigative Medicine High Impact Case Reports, 2023, Vol.11, no. - 10.1177/23247096231188243; Haney E., Trimble M., Cheng J., Vallé Q.,Hancock R. Critical Assessment of Methods to Quantify Biofilm Growth and Evaluate Antibiofilm Activity of Host Defence Peptides. Biomolecules, 2018, Vol.8, no 2. - 10.3390/biom8020029; Hilliard J.J., Datta V., Tkaczyk C., Hamilton M., Sadowska A., Jones-Nelson O., O'Day T., Weiss W.J., Szarka S., Nguyen V., Prokai L., Suzich J., Stover C.K.,Sellman B.R. Anti-Alpha-Toxin Monoclonal Antibody and Antibiotic Combination Therapy Improves Disease Outcome and Accelerates Healing in a Staphylococcus aureus Dermonecrosis Model. Antimicrobial Agents and Chemotherapy, 2015, Vol.59, no 1, pp. 299-309. - 10.1128/aac.03918-14; Hoffman L.R., D'Argenio D.A., MacCoss M.J., Zhang Z., Jones R.A.,Miller S.I. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature, 2005, Vol.436, no 7054, pp. 1171-5. - 10.1038/nature03912; Høiby N., Bjarnsholt T., Givskov M., Molin S.,Ciofu O. Antibiotic resistance of bacterial biofilms. International Journal of Antimicrobial Agents, 2010, Vol.35, no 4, pp. 322-332. - 10.1016/j.ijantimicag.2009.12.011; Hooper D.C.,Jacoby G.A. Mechanisms of drug resistance: quinolone resistance. Annals of the New York Academy of Sciences, 2015, Vol.1354, no 1, pp. 12-31. - 10.1111/nyas.12830; Horton D., Wander J.D.,Foltz R.L. Chemical-ionization mass spectrometry of lincomycin and clindamycin. Analytical Biochemistry, 1974, Vol.59, no 2, pp. 452-461. - 10.1016/0003-2697(74)90298-x; Ichikawa M., Nakamoto N., Kredo-Russo S., Weinstock E., Weiner I.N., Khabra E., Ben-Ishai N., Inbar D., Kowalsman N., Mordoch R., Nicenboim J., Golembo M., Zak N., Jablonska J., Sberro-Livnat H., Navok S., Buchshtab N., Suzuki T., Miyamoto K., Teratani T., Fujimori S., Aoto Y., Konda M., Hayashi N., Chu P.-S., Taniki N., Morikawa R., Kasuga R., Tabuchi T., Sugimoto S., Mikami Y., Shiota A., Bassan M.,Kanai T. Bacteriophage therapy against pathological Klebsiella pneumoniae ameliorates the course of primary sclerosing cholangitis. Nature Communications, 2023, Vol.14, no 1. - 10.1038/s41467-023-39029-9; Jong A.Y., Wu C.H., Li J., Sun J., Fabbri M., Wayne A.S.,Seeger R.C. Large‐scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells. Journal of Extracellular Vesicles, 2017, Vol.6, no 1. - 10.1080/20013078.2017.1294368; Kang H.-K.,Park Y. Glycopeptide Antibiotics: Structure and Mechanisms of Action. Journal of Bacteriology and Virology, 2015, Vol.45, no 2. - 10.4167/jbv.2015.45.2.67; Kannan K., Vazquez-Laslop N.,Mankin A.S. Selective protein synthesis by ribosomes with a drug-obstructed exit tunnel. Cell, 2012, Vol.151, no 3, pp. 508-20. - 10.1016/j.cell.2012.09.018; Karballaei Mirzahosseini H., Hadadi-Fishani M., Morshedi K.,Khaledi A. Meta-Analysis of Biofilm Formation, Antibiotic Resistance Pattern, and Biofilm-Related Genes in Pseudomonas aeruginosa Isolated from Clinical Samples. Microbial Drug Resistance, 2020, Vol.26, no 7, pp. 815-824. - 10.1089/mdr.2019.0274; Kishk R., Soliman N., Nemr N., Eldesouki R., Mahrous N., Gobouri A., Azab E.,Anani M. Prevalence of Aminoglycoside Resistance and Aminoglycoside Modifying Enzymes in Acinetobacter baumannii Among Intensive Care Unit Patients, Ismailia, Egypt. Infection and Drug Resistance, 2021, Vol.Volume 14, no, pp. 143-150. - 10.2147/idr.S290584; Klingemann H. The NK-92 cell line—30 years later: its impact on natural killer cell research and treatment of cancer. Cytotherapy, 2023, Vol.25, no 5, pp. 451-457. - 10.1016/j.jcyt.2022.12.003; Korenevsky A.V., Shcherbitskaia A.D., Berezkina M.E., Markova K.L., Alexandrova E.P., Balabas O.A., Selkov S.A.,Sokolov D.I. MALDI-TOF mass spectrometric protein profiling of microvesicles produced by the NK-92 natural killer cell line. Medical Immunology (Russia), 2020, Vol.22, no 4, pp. 633-646. - 10.15789/1563-0625-mms-1976; Lamichhane T.N., Raiker R.S.,Jay S.M. Exogenous DNA Loading into Extracellular Vesicles via Electroporation is Size-Dependent and Enables Limited Gene Delivery. Mol Pharm, 2015, Vol.12, no 10, pp. 3650-7. - 10.1021/acs.molpharmaceut.5b00364; Ledger E.V.K., Sabnis A.,Edwards A.M. Polymyxin and lipopeptide antibiotics: membrane-targeting drugs of last resort. Microbiology, 2022, Vol.168, no 2. - 10.1099/mic.0.001136; León D.L., Fellay I., Mantel P.-Y.,Walch M., Killing Bacteria with Cytotoxic Effector Proteins of Human Killer Immune Cells: Granzymes, Granulysin, and Perforin, in Bacterial Pathogenesis. 2017. p. 275-284. -; Lin Q., Deslouches B., Montelaro R.C.,Di Y.P. Prevention of ESKAPE pathogen biofilm formation by antimicrobial peptides WLBU2 and LL37. Int J Antimicrob Agents, 2018, Vol.52, no 5, pp. 667-672. - 10.1016/j.ijantimicag.2018.04.019; Luo G., Zhang J., Wang H., Sun Y., Cheng B., Xu Z., Zhang Y., Li H., Lu W., Nemeth E., Ganz T.,Fang X. Human defensin-inspired discovery of peptidomimetic antibiotics. Proc Natl Acad Sci U S A, 2022, Vol.119, no 10, pp. e2117283119. - 10.1073/pnas.2117283119; Luquero A., Vilahur G., Crespo J., Badimon L.,Borrell‐Pages M. Microvesicles carrying LRP5 induce macrophage polarization to an anti‐inflammatory phenotype. Journal of Cellular and Molecular Medicine, 2021, Vol.25, no 16, pp. 7935-7947. - 10.1111/jcmm.16723; Mankin A.S. Nascent peptide in the "birth canal" of the ribosome. Trends Biochem Sci, 2006, Vol.31, no 1, pp. 11-3. - 10.1016/j.tibs.2005.11.007; Matzov D., Eyal Z., Benhamou R.I., Shalev-Benami M., Halfon Y., Krupkin M., Zimmerman E., Rozenberg H., Bashan A., Fridman M.,Yonath A. Structural insights of lincosamides targeting the ribosome of Staphylococcus aureus. Nucleic Acids Research, 2017, Vol.45, no 17, pp. 10284-10292. - 10.1093/nar/gkx658; Mingeot-Leclercq M.P., Glupczynski Y.,Tulkens P.M. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother, 1999, Vol.43, no 4, pp. 727-37. - 10.1128/AAC.43.4.727; Mohr K.I. History of Antibiotics Research. Curr Top Microbiol Immunol, 2016, Vol.398, no, pp. 237-272. - 10.1007/82_2016_499; Morin A.M., Kerwat K.M., Klotz M., Niestolik R., Ruf V.E., Wulf H., Zimmermann S.,Eberhart L.H. Risk factors for bacterial catheter colonization in regional anaesthesia. BMC Anesthesiol, 2005, Vol.5, no 1, pp. 1. - 10.1186/1471-2253-5-1; Nasser M., Palwe S., Bhargava R.N., Feuilloley M.G.J.,Kharat A.S. Retrospective Analysis on Antimicrobial Resistance Trends and Prevalence of beta-lactamases in Escherichia coli and ESKAPE Pathogens Isolated from Arabian Patients during 2000-2020. Microorganisms, 2020, Vol.8, no 10. - 10.3390/microorganisms8101626; National Nosocomial Infections Surveillance S. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control, 2004, Vol.32, no 8, pp. 470-85. - 10.1016/S0196655304005425; Nelson M.L.,Levy S.B. The history of the tetracyclines. Ann N Y Acad Sci, 2011, Vol.1241, no, pp. 17-32. - 10.1111/j.1749-6632.2011.06354.x; Neu H.C. Relation of structural properties of beta-lactam antibiotics to antibacterial activity. Am J Med, 1985, Vol.79, no 2A, pp. 2-13. - 10.1016/0002-9343(85)90254-2; Nikaido H.,Rosenberg E.Y. Porin channels in Escherichia coli: studies with liposomes reconstituted from purified proteins. J Bacteriol, 1983, Vol.153, no 1, pp. 241-52. - 10.1128/jb.153.1.241-252.1983; Pathania R., Sharma A.,Gupta V. Efflux pump inhibitors for bacterial pathogens: From bench to bedside. Indian Journal of Medical Research, 2019, Vol.149, no 2. - 10.4103/ijmr.IJMR_2079_17; Pham T.D.M., Ziora Z.M.,Blaskovich M.A.T. Quinolone antibiotics. Medchemcomm, 2019, Vol.10, no 10, pp. 1719-1739. - 10.1039/c9md00120d; Pirnay J.-P., Djebara S., Steurs G., Griselain J., Cochez C., De Soir S., Glonti T., Spiessens A., Berghe E.V., Green S., Wagemans J., Lood C., Schrevens E., Chanishvili N., Kutateladze M., de Jode M., Ceyssens P.-J., Draye J.-P., Verbeken G., De Vos D., Rose T., Onsea J., Van Nieuwenhuyse B., Soentjens P., Lavigne R.,Merabishvili M. 2023 no. - 10.1101/2023.08.28.23294728; Plé C., Tam H.-K., Vieira Da Cruz A., Compagne N., Jiménez-Castellanos J.-C., Müller R.T., Pradel E., Foong W.E., Malloci G., Ballée A., Kirchner M.A., Moshfegh P., Herledan A., Herrmann A., Deprez B., Willand N., Vargiu A.V., Pos K.M., Flipo M.,Hartkoorn R.C. Pyridylpiperazine-based allosteric inhibitors of RND-type multidrug efflux pumps. Nature Communications, 2022, Vol.13, no 1. - 10.1038/s41467-021-27726-2; Postma D.F., van Werkhoven C.H., van Elden L.J., Thijsen S.F., Hoepelman A.I., Kluytmans J.A., Boersma W.G., Compaijen C.J., van der Wall E., Prins J.M., Oosterheert J.J., Bonten M.J.,Group C.-S.S. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med, 2015, Vol.372, no 14, pp. 1312-23. - 10.1056/NEJMoa1406330; Poulou A., Voulgari E., Vrioni G., Koumaki V., Xidopoulos G., Chatzipantazi V., Markou F.,Tsakris A. Outbreak caused by an ertapenem-resistant, CTX-M-15-producing Klebsiella pneumoniae sequence type 101 clone carrying an OmpK36 porin variant. J Clin Microbiol, 2013, Vol.51, no 10, pp. 3176-82. - 10.1128/JCM.01244-13; Pradel E.,Pages J.M. The AcrAB-TolC efflux pump contributes to multidrug resistance in the nosocomial pathogen Enterobacter aerogenes. Antimicrob Agents Chemother, 2002, Vol.46, no 8, pp. 2640-3. - 10.1128/AAC.46.8.2640-2643.2002; Rice L.B. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis, 2008, Vol.197, no 8, pp. 1079-81. - 10.1086/533452; Sahly H., Schubert S., Harder J., Kleine M., Sandvang D., Ullmann U., Schroder J.M.,Podschun R. Activity of human beta-defensins 2 and 3 against ESBL-producing Klebsiella strains. J Antimicrob Chemother, 2006, Vol.57, no 3, pp. 562-5. - 10.1093/jac/dkl003; Santajit S.,Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. BioMed Research International, 2016, Vol.2016, no, pp. 1-8. - 10.1155/2016/2475067; Sauer K., Stoodley P., Goeres D.M., Hall-Stoodley L., Burmølle M., Stewart P.S.,Bjarnsholt T. The biofilm life cycle: expanding the conceptual model of biofilm formation. Nature Reviews Microbiology, 2022, Vol.20, no 10, pp. 608-620. - 10.1038/s41579-022-00767-0; Spížek J.,Řezanka T. Lincosamides: Chemical structure, biosynthesis, mechanism of action, resistance, and applications. Biochemical Pharmacology, 2017, Vol.133, no, pp. 20-28. - 10.1016/j.bcp.2016.12.001; Stephens C.R., Conover L.H., Hochstein F.A., Regna P.P., Pilgrim F.J., Brunings K.J.,Woodward R.B. Terramycin. Viii. Structure of Aureomycin and Terramycin. Journal of the American Chemical Society, 2002, Vol.74, no 19, pp. 4976-4977. - 10.1021/ja01139a533; Suresh M.K., Biswas R.,Biswas L. An update on recent developments in the prevention and treatment of Staphylococcus aureus biofilms. International Journal of Medical Microbiology, 2019, Vol.309, no 1, pp. 1-12. - 10.1016/j.ijmm.2018.11.002; Sutterwala Fayyaz S., Secher T., Fas S., Fauconnier L., Mathieu M., Rutschi O., Ryffel B.,Rudolf M. The Anti-Pseudomonas aeruginosa Antibody Panobacumab Is Efficacious on Acute Pneumonia in Neutropenic Mice and Has Additive Effects with Meropenem. PLoS ONE, 2013, Vol.8, no 9. - 10.1371/journal.pone.0073396; Tacconelli E., Carrara E., Savoldi A., Harbarth S., Mendelson M., Monnet D.L., Pulcini C., Kahlmeter G., Kluytmans J., Carmeli Y., Ouellette M., Outterson K., Patel J., Cavaleri M., Cox E.M., Houchens C.R., Grayson M.L., Hansen P., Singh N., Theuretzbacher U., Magrini N.,Group W.H.O.P.P.L.W. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis, 2018, Vol.18, no 3, pp. 318-327. - 10.1016/S1473-3099(17)30753-3; Tai K.P., Kamdar K., Yamaki J., Le V.V., Tran D., Tran P., Selsted M.E., Ouellette A.J.,Wong-Beringer A. Microbicidal effects of alpha- and theta-defensins against antibiotic-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Innate Immun, 2015, Vol.21, no 1, pp. 17-29. - 10.1177/1753425913514784; Tehrani K.H.M.E.,Martin N.I. β-lactam/β-lactamase inhibitor combinations: an update. MedChemComm, 2018, Vol.9, no 9, pp. 1439-1456. - 10.1039/c8md00342d; Tu D., Blaha G., Moore P.B.,Steitz T.A. Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell, 2005, Vol.121, no 2, pp. 257-70. - 10.1016/j.cell.2005.02.005; Valore E.V., Park C.H., Quayle A.J., Wiles K.R., McCray P.B., Jr.,Ganz T. Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. J Clin Invest, 1998, Vol.101, no 8, pp. 1633-42. - 10.1172/JCI1861; Vazquez-Laslop N.,Mankin A.S. How Macrolide Antibiotics Work. Trends Biochem Sci, 2018, Vol.43, no 9, pp. 668-684. - 10.1016/j.tibs.2018.06.011; Velkov T., Gallardo-Godoy A., Swarbrick J.D., Blaskovich M.A.T., Elliott A.G., Han M., Thompson P.E., Roberts K.D., Huang J.X., Becker B., Butler M.S., Lash L.H., Henriques S.T., Nation R.L., Sivanesan S., Sani M.-A., Separovic F., Mertens H., Bulach D., Seemann T., Owen J., Li J.,Cooper M.A. Structure, Function, and Biosynthetic Origin of Octapeptin Antibiotics Active against Extensively Drug-Resistant Gram-Negative Bacteria. Cell Chemical Biology, 2018, Vol.25, no 4, pp. 380-391.e5. - 10.1016/j.chembiol.2018.01.005; Verma P., Tiwari M.,Tiwari V. Efflux pumps in multidrug-resistant Acinetobacter baumannii: Current status and challenges in the discovery of efflux pumps inhibitors. Microbial Pathogenesis, 2021, Vol.152, no. - 10.1016/j.micpath.2021.104766; Waksman S.A. What is an Antibiotic or an Antibiotic Substance? Mycologia, 2018, Vol.39, no 5, pp. 565-569. - 10.1080/00275514.1947.12017635; Walch M., Dotiwala F., Mulik S., Thiery J., Kirchhausen T., Clayberger C., Krensky Alan M., Martinvalet D.,Lieberman J. Cytotoxic Cells Kill Intracellular Bacteria through Granulysin-Mediated Delivery of Granzymes. Cell, 2014, Vol.157, no 6, pp. 1309-1323. - 10.1016/j.cell.2014.03.062; Waxman D.J.,Strominger J.L. Penicillin-Binding Proteins and the Mechanism of Action of Beta-Lactam Antibiotics. Annual Review of Biochemistry, 1983, Vol.52, no 1, pp. 825-869. - 10.1146/annurev.bi.52.070183.004141; Wei Z., Zhang X., Yong T., Bie N., Zhan G., Li X., Liang Q., Li J., Yu J., Huang G., Yan Y., Zhang Z., Zhang B., Gan L., Huang B.,Yang X. Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles. Nature Communications, 2021, Vol.12, no 1. - 10.1038/s41467-020-20723-x; Williams B.A., Law A.D., Routy B., denHollander N., Gupta V., Wang X.-H., Chaboureau A., Viswanathan S.,Keating A. A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. Oncotarget, 2017, Vol.8, no 51, pp. 89256-89268. - 10.18632/oncotarget.19204; Wilson D.N., Schluenzen F., Harms J.M., Starosta A.L., Connell S.R.,Fucini P. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc Natl Acad Sci U S A, 2008, Vol.105, no 36, pp. 13339-44. - 10.1073/pnas.0804276105; Wozniak A., Villagra N.A., Undabarrena A., Gallardo N., Keller N., Moraga M., Roman J.C., Mora G.C.,Garcia P. Porin alterations present in non-carbapenemase-producing Enterobacteriaceae with high and intermediate levels of carbapenem resistance in Chile. J Med Microbiol, 2012, Vol.61, no Pt 9, pp. 1270-1279. - 10.1099/jmm.0.045799-0; Xiong Z., Zhu D., Wang F., Zhang Y., Okamoto R.,Inoue M. Investigation of extended-spectrum beta-lactamase in Klebsiellae pneumoniae and Escherichia coli from China. Diagn Microbiol Infect Dis, 2002, Vol.44, no 2, pp. 195-200. - 10.1016/s0732-8893(02)00441-8; Xu X., Weiss I.D., H. Zhang H., Singh S.P., Wynn T.A., Wilson M.S.,Farber J.M. Conventional NK Cells Can Produce IL-22 and Promote Host Defense in Klebsiella pneumoniae Pneumonia. The Journal of Immunology, 2014, Vol.192, no 4, pp. 1778-1786. - 10.4049/jimmunol.1300039; Yan F., He S., Han X., Wang J., Tian X., Wang C., James T.D., Cui J., Ma X.,Feng L. High-throughput fluorescent screening of beta-lactamase inhibitors to improve antibiotic treatment strategies for tuberculosis. Biosens Bioelectron, 2022, Vol.216, no, pp. 114606. - 10.1016/j.bios.2022.114606; Zárate S., De la Cruz Claure M., Benito-Arenas R., Revuelta J., Santana A.,Bastida A. Overcoming Aminoglycoside Enzymatic Resistance: Design of Novel Antibiotics and Inhibitors. Molecules, 2018, Vol.23, no 2. - 10.3390/molecules23020284; Zhang F., Zhuang J., Li Z., Gong H., de Avila B.E., Duan Y., Zhang Q., Zhou J., Yin L., Karshalev E., Gao W., Nizet V., Fang R.H., Zhang L.,Wang J. Nanoparticle-modified microrobots for in vivo antibiotic delivery to treat acute bacterial pneumonia. Nat Mater, 2022, Vol.21, no 11, pp. 1324-1332. - 10.1038/s41563-022-01360-9; Zhao H., Shao D., Jiang C., Shi J., Li Q., Huang Q., Rajoka M.S.R., Yang H.,Jin M. Biological activity of lipopeptides from Bacillus. Applied Microbiology and Biotechnology, 2017, Vol.101, no 15, pp. 5951-5960. - 10.1007/s00253-017-8396-0; Zhao W.H.,Hu Z.Q. Epidemiology and genetics of CTX-M extended-spectrum beta-lactamases in Gram-negative bacteria. Crit Rev Microbiol, 2013, Vol.39, no 1, pp. 79-101. - 10.3109/1040841X.2012.691460; https://www.mimmun.ru/mimmun/article/view/2945Test